tiprankstipranks
InflaRx announces INF904 development plans
PremiumThe FlyInflaRx announces INF904 development plans
1M ago
InflaRx sees cash runway into at least 2026
PremiumThe Fly
InflaRx sees cash runway into at least 2026
1M ago
InflaRx reports 2023 EPS (EUR 0.78) vs. (EUR 0.67) last year
PremiumThe Fly
InflaRx reports 2023 EPS (EUR 0.78) vs. (EUR 0.67) last year
1M ago
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
PremiumPress ReleasesInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
3M ago
InflaRx announces initiation of its commitment program for GOHIBIC
PremiumThe Fly
InflaRx announces initiation of its commitment program for GOHIBIC
3M ago
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
PremiumPress Releases
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4M ago
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress ReleasesInflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
6M ago
InflaRx reports Q3 EPS (EUR 0.13) vs (EUR 0.18) last year
PremiumThe Fly
InflaRx reports Q3 EPS (EUR 0.13) vs (EUR 0.18) last year
6M ago
InflaRx announces results from its SAD Phase I study with INF904
PremiumThe Fly
InflaRx announces results from its SAD Phase I study with INF904
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100